MLN9708
![]() |
- ₹0
- Product name: MLN9708
- CAS: 1201902-80-8
- MF: C20H23BCl2N2O9
- MW: 517.12
- EINECS:-0
- MDL Number:MFCD18251437
- Synonyms:4-(carboxymethyl)-2-((R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)-6-oxo-1,3,2-dioxaborinane-4-carboxylic acid;MLN9708;MLN9708,MLN-9708,MLN 9708;4-Carboxy-2-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-6-oxo-1,3,2-dioxaborinane-4-acetic acid;4-Carboxy-2-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-6-oxo-1,3,2-dioxaborinane-4-acetic acid MLN9708;Ixazomib Citrate;MLN9708;MLN-9708;4-(Carboxymethyl)-2-((R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)-6-oxo-1,3,2-dio
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|
Properties
Melting point :>227°C (dec.)
Density :1.47
storage temp. :Hygroscopic, -20°C Freezer, Under inert atmosphere
solubility :DMSO (Slightly), Methanol (Slightly, Heated, Sonicated)
pka :1.92±0.20(Predicted)
form :Solid
color :White to Off-White
Density :1.47
storage temp. :Hygroscopic, -20°C Freezer, Under inert atmosphere
solubility :DMSO (Slightly), Methanol (Slightly, Heated, Sonicated)
pka :1.92±0.20(Predicted)
form :Solid
color :White to Off-White
Safety Information
Symbol(GHS): |
![]() |
|||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | |||||||||||||||||||||||||||||||||||
Hazard statements: |
|
|||||||||||||||||||||||||||||||||||
Precautionary statements: |
|
Description
MLN9708 is an orally bioavailable prodrug of the second-generation proteasome inhibitor MLN2239 . This prodrug rapidly hydrolyzes in plasma to the biologically active form, which inhibits the β5 chymotryptic-like subunit of the 20S proteasome (IC50 = 3.4 nM; Ki = 0.93 nM in cell-free assays). It inhibits the β1 caspase-like and β2 trypsin-like proteolytic sites with IC50 values of 0.03 and 3.5 μM, respectively. MLN9708 has shown antitumor activity both in cell-based assays and in xenograft models and has been examined in phase III clinical trials for potential antimyeloma activity.More related product prices
ABT 263 CEP-18770 ONX-0912 1072833-77-2 Bortezomib Boric acid Pazopanib Tigecycline Azilsartan NS-398 Alisertib (MLN8237) 905579-51-3 CarfilzomibRelated product price
- Bortezomib
₹12940 - Pazopanib
₹7393.48-33730.7 - Tigecycline
₹7200-22342.8